MAM
DMRA

Marquette Asset Management’s Damora Therapeutics DMRA Stock Holding History

Marquette Asset Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,410
Closed -$114K – 244
2022
Q3 		$114K Hold
2,410
– – 0.04% 98
2022
Q2 		$104K Buy
2,410
+579
+32% +$26.6K 0.03% 127
2022
Q1 		$101K Buy
1,831
+371
+25% +$20.8K 0.02% 146
2021
Q4 		$111K Buy
1,460
+495
+51% +$38.9K 0.02% 143
2021
Q3 		$87K Buy
+965
New +$103K 0.02% 150

Other funds holding DMRA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Marquette Asset Management's DMRA Position: Q4 2022 in Review

Marquette Asset Management sold out of Damora Therapeutics (DMRA) in Q4 2022, closing a stake of 2,410 shares — an estimated $114K sold.

Marquette Asset Management first reported a position in DMRA in Q3 2021 and held it in 5 quarters. The position peaked at $114K in Q3 2022. 22 funds tracked by Wall St. Rank hold DMRA as of Q4 2022.

  • Marquette Asset Management reported no remaining Damora Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Marquette Asset Management sold 2,410 Damora Therapeutics shares in Q4 2022, an estimated $114K.
  • Marquette Asset Management first reported a position in Damora Therapeutics in Q3 2021 and held it in 5 quarters.
  • Marquette Asset Management's Damora Therapeutics position peaked at $114K in Q3 2022.
  • 22 funds tracked by Wall St. Rank held Damora Therapeutics as of Q4 2022.

Based on Marquette Asset Management's 13F filing for Q4 2022, filed 12 Jan 2023.